PNPLA3 I148M and TM6SF2 E167K variants might correlated with the decreased risk of CHD in NAFLD patients by associated with the reduced serum lipid levels. This evidence concerns the gene TM6SF2 and metabolic dysfunction-associated steatotic liver disease.